@misc{pan_wu_yin_tang_zhang_feng_chen_mossel_2020, 
  title={CHI3L1 Expression is a Prognostic Marker for Patients with Diagnosed Solid Tumors: Evidence from a Systematic Review and Meta-Analysis}, 
  DOI={10.21203/rs.3.rs-26219/v1}, 
  abstractNote={<jats:title>Abstract</jats:title>
        <jats:p><jats:bold>Background: </jats:bold>Accumulating studies have demonstrated YKL-40 associated with the prognosis of several cancers and contributed to the tumor progression through promoting tumor angiogenesis, migration, invasion and metastasis. The objective of this meta-analysis was to investigatethe relationship between YKL-40 and prognosis inpatients with solid tumors and seek for a new prognostic biomarker.<jats:bold>Method: </jats:bold>Relevant studies were searched in the Medline (PubMed), Web of science, and Embase. Pooled HR of overall survival and disease-free survival (DFS) were calculated to evaluate the strengthof the association between YKL-40 and cancer prognosis by using Stata software 14.0.<jats:bold>Results:</jats:bold> In total, 30 studies comprising 5160 patients were considered eligible and enrolled into the final meta-analysis. According to the meta-analysis results, higher expression of YKL-40 predicted poorer OS (pooled HR=1.85 CI%=1.58-2.18;P&lt;0.001) and DFS (pooled HR =3.63 95% CI =2.63-5.01; P&lt;0.001).<jats:bold>Conclusion: </jats:bold>The current evidence suggests that YKL-40 has a predictive effect onsurvival of cancer patients as indexed by DFS and OS. YKL-40 tissue expression is a valuable prognostic biomarker and may be a promising therapeutic target for solid tumors.</jats:p>}, 
  publisher={Research Square}, 
  author={pan, jianyuan and Wu, Liping and Yin, Shiwu and Tang, Yongqin and Zhang, Jing and Feng, Jun and Chen, Zhenfei and Mossel, Marije}, 
  year={2020}, 
  month={May}
  }